Ocriplasmin for Vitreoretinal Diseases
Joint Authors
Rahimy, Ehsan
Tsui, Irena
Schwartz, Steven D.
Pan, Carolyn K.
Source
Journal of Biomedicine and Biotechnology
Issue
Vol. 2012, Issue 2012 (31 Dec. 2012), pp.1-6, 6 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2012-10-14
Country of Publication
Egypt
No. of Pages
6
Main Subjects
Abstract EN
Fibronectin and laminin are clinically relevant plasmin receptors in the eye.
Located at the vitreoretinal interface, they are cleaved by ocriplasmin (Microplasmin, ThromboGenics, Iselin, NJ), a novel ophthalmic medication.
A series of clinical trials to study ocriplasmin for the treatment of vitreoretinal diseases such as vitreomacular traction, macular hole, and exudative age-related macular degeneration are underway.
The results are promising and may impact patient care.
American Psychological Association (APA)
Tsui, Irena& Pan, Carolyn K.& Rahimy, Ehsan& Schwartz, Steven D.. 2012. Ocriplasmin for Vitreoretinal Diseases. Journal of Biomedicine and Biotechnology،Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-465358
Modern Language Association (MLA)
Tsui, Irena…[et al.]. Ocriplasmin for Vitreoretinal Diseases. Journal of Biomedicine and Biotechnology No. 2012 (2012), pp.1-6.
https://search.emarefa.net/detail/BIM-465358
American Medical Association (AMA)
Tsui, Irena& Pan, Carolyn K.& Rahimy, Ehsan& Schwartz, Steven D.. Ocriplasmin for Vitreoretinal Diseases. Journal of Biomedicine and Biotechnology. 2012. Vol. 2012, no. 2012, pp.1-6.
https://search.emarefa.net/detail/BIM-465358
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-465358
